Niox

Other, 1740 Dell Range BLVD 439, The Oxford Science Park, Wyoming, 82009, United States, 51-200 Employees

Phone Number: 86********

Who is NIOX

NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX ...

Get Full Access

Headquarters: 1740 Dell Range BLVD 439, The Oxford Science Park, Wyoming, 82009, United States
Date Founded: 2006
Employees: 51-200
Revenue: $1 Million to $5 Million
Active Tech Stack: See technologies

Industry: Other

SIC Code: 2834

Does something look wrong? Fix it. | View contact records from NIOX

NIOX Org Chart and Mapping

Employees

Martha Pierre

Territory Business Manager, Medical Device and Biopharmaceutical Sales

Email
Phone

John Chauvin

Senior Product Support Technician

Email
Phone

Allan Badulis

Director, Global Research Business

Email
Phone

Keaton Rich

Territory Sales Representative

Email
Phone

See Full Org Chart

View Email Formats for NIOX

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding NIOX

Answer: NIOX's headquarters are located at 1740 Dell Range BLVD 439, The Oxford Science Park, Wyoming, 82009, United States

Answer: NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma. NIOX VERO provides accurate and reliable results, allowing healthcare professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, with a simple touch screen interface and intuitive design, and can be used in a variety of settings, including clinics, hospitals, and primary care settings. The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX is also committed to offering additional training and support for healthcare professionals. Overall, NIOX Group plc is the global leader in FeNO testing, with a strong reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO, healthcare professionals have a reliable and non-invasive1 tool to help them better diagnose and manage asthma. References: 1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO: randomized studies in asthma. Pulm Ther. 2017;3:207-218. 2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1 3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173. 4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. 5